EGFR and non-small cell lung carcinoma: In another study by Yeo et al., a decrease dose of erlotinib from 150 mg/d to 25 mg/d (equivalent to gefitinib 250 mg/d) in MT EGFR NSCLC patients showed a similar response rate but fewer side-effects15.